Media Statements

PARIS, FRANCE, March 13th, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today it has been assigned long-term credit ratings of Baa3 by Moody’s and BBB- by S&P Global Ratings, both with a “Stable” outlook. 

This important medicine, and all associated activities, will be transferred to Eton Pharmaceuticals following the signing of an asset transfer agreement. This agreement is expected to complete at the end of 2024.

PARIS, FRANCE, 27 August 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) has entered into an agreement to sell its rare pediatric disease Priority Review Voucher (PRV) to a large global pharmaceutical company. Ipsen received the PRV coinciding with the SohonosTM…

On Wednesday 21 June, David Loew was elected second Vice President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Yesterday’s appointments also included Lars Fruergaard Jørgensen, Chief Executive of Novo Nordisk, as EFPIA President, and Stefan Oelrich, Head…

In keeping with Ipsen’s drive to accelerate the research and development of transformative therapies, we are pleased to announce a new research collaboration agreement with Medetia, a biotech with extensive drug discovery and medicinal chemistry experience, located at the Imagine Institute…